^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imjudo (tremelimumab-actl)

    i
    Other names: PF06753388, CP675206, CP 675206, CP-675206, CP-675,206, CP-675, PF-06753388, CP 675, CP675, PF 06753388
    Company:
    AstraZeneca, Pfizer
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    1d
    Durvalumab and Tremelimumab for Pediatric Malignancies (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Feb 2026 --> Feb 2027 | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)
    3d
    Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) (2024-513219-29-00)
    P2/3, N=203, Recruiting, University College London | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    5d
    IMFINZI-subQ: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    ADAPT-BLADDER: Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Noah Hahn, M.D. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • gemcitabine • docetaxel • Imjudo (tremelimumab-actl)
    7d
    Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (clinicaltrials.gov)
    P2, N=535, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Sep 2026 --> Apr 2026
    Enrollment open • Trial initiation date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Krazati (adagrasib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    14d
    Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov)
    P3, N=226, Recruiting, NRG Oncology | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    |
    IL2 (Interleukin 2)
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • ABP 206 (nivolumab biosimilar)
    15d
    Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=68, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion • pMMR
    |
    MSI (Microsatellite instability)
    |
    Imfinzi (durvalumab) • docetaxel • Imjudo (tremelimumab-actl) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    15d
    Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, OHSU Knight Cancer Institute
    New P2 trial
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • zanzalintinib (XL092)
    18d
    KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma. (PubMed, Eur Urol)
    CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.
    Journal • PD(L)-1 Biomarker
    |
    KIM1 (Kidney injury molecule 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)
    21d
    INFINITY: TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Not yet recruiting --> Active, not recruiting
    Enrollment closed • MSI-H
    |
    MSI-H/dMMR
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    21d
    Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma. (PubMed, J Immunother Cancer)
    Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte-NK cytotoxic axes, whereas Dur/Tre enhances monocyte-T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PRKCH (Protein Kinase C Eta) • CD14 (CD14 Molecule) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)